We are live on ! Find out more
RARE icon

Ultragenyx Pharmaceutical
RARE

171 hedge funds and large institutions have $3.98B invested in Ultragenyx Pharmaceutical in 2015 Q4 according to their latest regulatory filings, with 25 funds opening new positions, 74 increasing their positions, 51 reducing their positions, and 15 closing their positions.

New
Increased
Maintained
Reduced
Closed

67% more first-time investments, than exits

New positions opened: 25 | Existing positions closed: 15

45% more repeat investments, than reductions

Existing positions increased: 74 | Existing positions reduced: 51

17% more capital invested

Capital invested by funds: $3.39B → $3.98B (+$590M)

6% more funds holding

Funds holding: 161 → 171 (+10)

0% more funds holding in top 10

Funds holding in top 10: 2 → 2 (0)

20% less call options, than puts

Call options by funds: $10.2M | Put options by funds: $12.8M

Holders
171
Holders Change
+10
Holders Change %
+6.21%
% of All Funds
4.49%
Holding in Top 10
2
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.05%
New
25
Increased
74
Reduced
51
Closed
15
Calls
$10.2M
Puts
$12.8M
Net Calls
-$2.61M
Net Calls Change
+$11.3M

Top Buyers

1
Wellington Management Group
Wellington Management Group
Massachusetts
+$42.1M
2
Vanguard Group
Vanguard Group
Pennsylvania
+$27.5M
3
Wells Fargo
Wells Fargo
California
+$22M
4
VOYA Investment Management
VOYA Investment Management
Georgia
+$19.5M
5
State Street
State Street
Massachusetts
+$12.7M

Top Sellers

1
TGHSA
TPG Group Holdings (SBS) Advisors
Texas
-$43.6M
2
Millennium Management
Millennium Management
New York
-$34.7M
3
Two Sigma Investments
Two Sigma Investments
New York
-$14.5M
4
Goldman Sachs
Goldman Sachs
New York
-$14.2M
5
CWAM
Columbia Wanger Asset Management
Illinois
-$14.1M
Name Holding Trade Value Shares
Change 		Change in
Stake
Axa
26
Axa
France
$28M +$11.9M +118,750 +91%
Geode Capital Management
27
Geode Capital Management
Massachusetts
$27.8M +$1.03M +10,287 +4%
JP Morgan Chase
28
JP Morgan Chase
New York
$27.2M +$6.04M +60,442 +33%
CCI
29
Columbus Circle Investors
$26.5M +$8.58M +85,781 +57%
BG
30
BlackRock Group
United Kingdom
$24.4M +$236K +2,362 +1%
VOYA Investment Management
31
VOYA Investment Management
Georgia
$23.8M +$19.5M +195,410 +1,183%
PC
32
Polar Capital
United Kingdom
$23.6M -$8.59M -85,879 -29%
WC
33
Weatherbie Capital
Massachusetts
$23.2M -$32.1K -321 -0.2%
Millennium Management
34
Millennium Management
New York
$21.8M -$34.7M -347,499 -64%
Bank of New York Mellon
35
Bank of New York Mellon
New York
$19.8M +$156K +1,556 +0.9%
BIM
36
BlackRock Investment Management
Delaware
$18.8M +$114K +1,140 +0.7%
Deutsche Bank
37
Deutsche Bank
Germany
$18.6M +$5.92M +59,173 +56%
TCIM
38
TIAA CREF Investment Management
New York
$17.8M +$43.2K +432 +0.3%
Charles Schwab
39
Charles Schwab
California
$17.3M +$1.15M +11,497 +8%
Allianz Asset Management
40
Allianz Asset Management
Germany
$16.7M -$2.97M -29,724 -17%
TA
41
Teachers Advisors
New York
$15.3M +$3.09M +30,866 +29%
BBA
42
Baker Bros. Advisors
New York
$13.9M – – –
IHM
43
Iguana Healthcare Management
New York
$12.9M +$500K +5,000 +5%
Brown Advisory
44
Brown Advisory
Maryland
$12.8M +$458K +4,584 +4%
FAM
45
Fred Alger Management
New York
$12.3M -$596K -5,965 -5%
OM
46
Opaleye Management
Massachusetts
$12.3M – – –
CAM
47
Cormorant Asset Management
Massachusetts
$12.3M – – –
RSCM
48
Rock Springs Capital Management
Maryland
$11.8M -$150K -1,500 -1%
Two Sigma Advisers
49
Two Sigma Advisers
New York
$10.3M -$6.68M -66,814 -42%
TCM
50
Tekla Capital Management
Massachusetts
$9.92M – – –
1
2
3 4 5

RARE Hedge Fund Activity: Q4 2015 in Review

171 of the 3,812 institutional investors tracked by Wall St. Rank reported a position in Ultragenyx Pharmaceutical (RARE) for Q4 2015, worth a combined $3.98B — up 17% from $3.39B a quarter earlier.

Buyers outnumbered sellers: 25 funds opened new RARE positions and 15 closed out — a net gain of 10 holders — while 74 added to existing stakes and 51 trimmed.

The largest buyer was Wellington Management Group, adding an estimated $42.1M. The largest seller was TPG Group Holdings (SBS) Advisors, exiting entirely with an estimated $43.6M sold.

  • 171 institutional investors held Ultragenyx Pharmaceutical (RARE) as of Q4 2015, up from 161 in Q3 2015.
  • Funds reported $3.98B of Ultragenyx Pharmaceutical stock for Q4 2015, up 17% quarter-over-quarter.
  • 25 funds opened new Ultragenyx Pharmaceutical positions in Q4 2015 and 15 closed out, a net change of +10 holders.
  • The largest Ultragenyx Pharmaceutical buyer in Q4 2015 was Wellington Management Group, an estimated $42.1M added.
  • The largest Ultragenyx Pharmaceutical seller in Q4 2015 was TPG Group Holdings (SBS) Advisors, an estimated $43.6M sold.

Based on aggregated 13F filings for Q4 2015.